Siramesine belongs to the group of lysosomotropic agents with potential therapeutic efficacy against COVID-19 by impacting cellular trafficking through the endosome/lysosome endocytic pathways and by promoting the accumulation of autophagosomes, which associate with a rapid and sustained inhibition of mTOR, a negative regulator of autophagy [76,77]. The gene discussed is MTOR; the disease is COVID-19.